BACKGROUND: As larger numbers of @entity101 @entity1 are screened for @entity1368 with the @entity1369 -to- @entity916 ratio (ARR), automated analyzers present a practical solution for many laboratories. We report the method-specific ARR cutoff determined with direct, automated chemiluminescence immunoassays allowing the simultaneous measurement of plasma @entity1369 concentrations (PACs) and plasma @entity916 concentrations (PRCs). METHODS: Method comparisons to commonly employed assays and tandem mass spectrometry were undertaken. @entity1 were previously diagnosed based on the local ARR cutoff of 1.2 (ng/dl)/( IU/ml) in samples collected in upright seated position. Lack of @entity1369 suppression in response to salt load to less than 5ng/dl confirmed @entity1368 . For the new assays, the optimal ARR cutoff was established in 152 @entity1 with essential @entity101 , 93 with @entity1368 and 147 normotensive @entity1 . @entity1369 suppression was assessed in 73 essential @entity101 and 46 @entity1368 @entity1 . RESULTS: @entity16180 and PRC were significantly correlated to values determined with currently available methods (P < 0.001). In @entity1 with @entity1368 , @entity1 with essential @entity101 and controls, mean (95% confidence interval) @entity16180 was 28.4 (25.4-31.8), 6.4 (5.9-6.9) and 6.2 (5.6-6.9)ng/dl, respectively. In the same groups, PRC was 6.6 (5.6-7.7), 12.9 (11.2-14.8) and 26.5 (22.2-31.5) IU/ml. An ARR cutoff of 1.12 provided 98.9% sensitivity and 78.9% specificity. Employing the new assay @entity1369 suppression confirmed the diagnosis of @entity1368 and essential @entity101 using the cutoff of 5ng/dl. CONCLUSION: Our data demonstrate that the new assays present a convenient alternative for the measurement of @entity16180 and PRC on a single automated analyzer. Availability of these simultaneous assays should facilitate screening and diagnosis of @entity1368 .

Clinical validation for the @entity1369 -to- XXXX ratio and @entity1369 suppression testing using simultaneous fully automated chemiluminescence immunoassays.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['Aldosterone', 'aldosterone'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity916 :: ('5972', 'Gene') :: ['renin'] @entity1368 :: ('MESH:D006929', 'Disease') :: ['primary aldosteronism'] @entity16180 :: ('D017239', 'Chemical') :: ['PAC']
@entity916 :: (5972,Gene) :: ['renin']
